Journal: Scientific Reports

Article Title: Oxyresveratrol suppressed melanogenesis, dendrite formation, and melanosome transport in melanocytes via regulation of the MC1R/cAMP/MITF pathway

doi: 10.1038/s41598-025-05248-x

Figure Lengend Snippet: Oxyresveratrol inhibited the expression of small GTPases and kinesin involved in dendrite formation and melanosome transport. ( a – h ) The effects of oxyresveratrol on the expression of eight genes associated with dendrite development and melanosome transport in B16F10 cells. OXY-5, 5 µg/mL oxyresveratrol group. OXY-10, 10 µg/mL oxyresveratrol group. OXY-15, 15 µg/mL oxyresveratrol group. The mRNA expression levels of Cdc42 , Rab17 , Rab11b , Rac1 , Kif5b , Rab27a , Mlph , and Myo5a were normalized to β-actin gene ( Actb ) levels. N = 3, Student’s t test, * P < 0.05, ** P < 0.01, *** P < 0.001 vs. CK. ( i ) The effects of oxyresveratrol on the protein expression of CDC42, RAB17, RAB11B, RAC1, KIF5B, and MLPH in B16F10 cells. The levels of these proteins were normalized to GAPDH levels.

Article Snippet: For western blot assay, antibodies CDC42 (10155-1-AP, 1:1000), RAC1 (24072-1-AP, 1:1000), MLPH (10338-1-AP, 1:1000), KIF5B (21632-1-AP, 1:1000), RAB11B (67780-1-Ig, 1:1000) and TRP-2 (13095-1-AP, 1:1000) were purchased from proteintech (China), RAB17 (TA350622S, 1:1000) and MC1R (TA321478S, 1:1000) were purchased from OriGene (USA), PMEL/gp100 (ab137078, 1:1000) was purchased from Abcam (UK), and GAPDH (KC-5G5, 1:10000) was purchased from Aksomics (China).

Techniques: Expressing

Journal: PloS one

Article Title: FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast.

doi: 10.1371/journal.pone.0112024

Figure Lengend Snippet: Figure 7. Immunohistochemical analysis of molecular apocrine markers derived from trancriptomics data within the apocrine cyst and carcinoma dataset. Representative staining of FFPE of apocrine cysts and IACs with antibodies against SLC2A10 (Glucose transporter type 10, sections A and B) - cytoplasmic immunoreactivity; SLC7A8 (L-type amino acid transporter 2, sections C and D) - mainly cytoplasmic and membranous immunereactivity; MLPH (Melanophilin, sections E and F) - cytoplasmic and luminal membranous immunoreactivity; FOXA1 (Hepatocyte nuclear factor 3-alpha, sections G and H) – nuclear staining; XBP1 (X-box-binding protein 1, sections I and J) – mainly nuclear and cytoplasmic immunereactivity; BLVRA (Biliverdin reductase A, sections K and L) - cytoplasmic immunoreactivity which combined with rare nuclear positivity; RHOB (Rho-related GTP-binding protein RhoB, sections M and N) - cytoplasmic immunoreactivity; TSC22D3 (TSC22 domain family protein 3, sections O and P) - mainly nuclear and cytoplasmic immunereactivity; ABCA12 (ATP-binding cassette sub-family A member 12, sections Q and R) - cytoplasmic immunoreactivity and SIDT1 (SID1 transmembrane family member 1, sections I and G) - cytoplasmic immunoreactivity. Magnification: x10. Representative areas are shown in higher magnification (x20) and examples of positive staining are indicated by red arrows. doi:10.1371/journal.pone.0112024.g007

Article Snippet: Antibodies The polyclonal antibody raised against synthetic peptides of human FABP7 (HPA028825), BLVRA (HPA042865), ABCA12 (HPA043194), SIDT1 (HPA035862), MLPH (HPA014685) were purchased from Atlas Antibodies and were used in IHC at a dilution of 1:200, 1:100, 1:500, 1:50 and 1:100 respectively in accordance to the manufacturer instructions.

Techniques: Immunohistochemical staining, Derivative Assay, Staining, Binding Assay

Journal: PloS one

Article Title: FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast.

doi: 10.1371/journal.pone.0112024

Figure Lengend Snippet: Figure 8. Protein expression profile of transcriptome-derived apocrine markers among breast cancer subtypes. The diagram presents immunohistochemical profiles of four breast tumor subtypes, TNBC, Luminal A Luminal B and HER2, reacted with antibodies against ten transcriptome-derived apocrine markers: XBP1, TSC22D3, ABCA12, SIDT1, FOXA1, RHOB, BLVRA, SLC2A10, SLC7A8 and MLPH. The rows indicate the expression of particular protein in every core in breast cancer TMA (BRC1501, 1502 and 1503; Pantomics INC, USA): red box – positive staining, white box – negative staining grey box – parameter was not determined. Corresponding frequencies of positives are shown on the right side of the diagram. Samples were considered as positive if 10% or more of the cells showed a clear positive staining with the antibodies. IDC = invasive ductal carcinoma; TNBC = triple negative breast cancer. Tumors have been stratified as specified in Materials and Methods. doi:10.1371/journal.pone.0112024.g008

Article Snippet: Antibodies The polyclonal antibody raised against synthetic peptides of human FABP7 (HPA028825), BLVRA (HPA042865), ABCA12 (HPA043194), SIDT1 (HPA035862), MLPH (HPA014685) were purchased from Atlas Antibodies and were used in IHC at a dilution of 1:200, 1:100, 1:500, 1:50 and 1:100 respectively in accordance to the manufacturer instructions.

Techniques: Expressing, Derivative Assay, Immunohistochemical staining, Staining, Negative Staining

Journal: PloS one

Article Title: FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast.

doi: 10.1371/journal.pone.0112024

Figure Lengend Snippet: Figure 9. MLPH is expressed by non-malignant apocrine cells but is lost in IACs. Representative images of FFPE sections immunostained with antibody against MLPH. (A) normal ducts, (B) benign apocrine cysts (mainly luminal membranous immunoreactivity), (C) sclerosing adenosis with apocrine differentiation, (D) IAC showing positive immunostaining in pseudo-glands structures (cytoplasmic and luminal membranous immunoreactivity) and (E) IAC with negative immunostaining. Magnification: x20. doi:10.1371/journal.pone.0112024.g009

Article Snippet: Antibodies The polyclonal antibody raised against synthetic peptides of human FABP7 (HPA028825), BLVRA (HPA042865), ABCA12 (HPA043194), SIDT1 (HPA035862), MLPH (HPA014685) were purchased from Atlas Antibodies and were used in IHC at a dilution of 1:200, 1:100, 1:500, 1:50 and 1:100 respectively in accordance to the manufacturer instructions.

Techniques: Immunostaining